278 related articles for article (PubMed ID: 28952704)
1. [Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].
Vinarov AZ; Spivak LG; Mironov AV
Urologiia; 2017 Sep; (4):120-128. PubMed ID: 28952704
[TBL] [Abstract][Full Text] [Related]
2. [Combination drug therapy in patients with BPH].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
[TBL] [Abstract][Full Text] [Related]
3. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
Walker A; Doyle S; Posnett J; Hunjan M
BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
[TBL] [Abstract][Full Text] [Related]
6. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
[TBL] [Abstract][Full Text] [Related]
7. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
8. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
10. [Medical treatment of patients with benign prostatic hyperplasia with 5-reductase inhibitors].
Spivak LG; Platonova DV; Yagudaev DD
Urologiia; 2019 Sep; (4):175-179. PubMed ID: 31535827
[TBL] [Abstract][Full Text] [Related]
11. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
Spivak LG; Lokshin KL; Vinarov AZ
Urologiia; 2015; (4):125-33. PubMed ID: 26665780
[TBL] [Abstract][Full Text] [Related]
12. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
13. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
14. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
15. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
[TBL] [Abstract][Full Text] [Related]
17. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy.
Masuda H; Mikami K; Otsuka K; Hou K; Suyama T; Araki K; Kojima S; Naya Y
Arch Ital Urol Androl; 2022 Dec; 94(4):521-524. PubMed ID: 36576460
[TBL] [Abstract][Full Text] [Related]
19. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
Haillot O; Fraga A; Maciukiewicz P; Pushkar D; Tammela T; Höfner K; Chantada V; Gagnier P; Morrill B
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):302-6. PubMed ID: 21502969
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.
Ismail M; Hashim H
Drugs Today (Barc); 2012 Jan; 48(1):17-24. PubMed ID: 22384457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
